News and Announcements
Novogen Annual Cost Savings Identified of$1.8M, Allowing for Greater Focus on R&D Investment
- Published August 18, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Novogen Ltd (ASX:NRT) an Australian oncology drug development company, have recently provided an update on the company’s business operations.
KEY TAKEAWAWAYS:
- Board and management have reviewed all business operations following the appointment of a new Chairman during June 2017.
- Approximately $1.8 million of annual cost savings identified, allowing greater focus on R&D investment.
- Shareholder feedback, depository holders instructed not to exercise “unvoted ADR proxies at future general meetings.
- The company has confirmed compliance with NASDAQ listing rules following revision of ADR consolidation ratio.
Novogen Chairman, Ian Ross, commented: “recent efforts have significantly improved the efficiency of Novogen as a business, and will allow us to better devote our resources to delivering on the substantial value that resides in our pipelined.”
“The company has taken on board and listened carefully to the feedback of shareholders, and has shown its commitment to delivering shareholder value in accordance with the best principles of corporate governance.”
Company Updates
The Algorithm Re-Dosing Cancer Treatment: Inside the University of Melbourne Spin-Out Rewriting a 60-Year-Old Formula
Oncology specialists are still calculating toxic chemotherapy doses using a formula from the era of the Ford Model T, leading to a system where seven out of eight patients are routinely overdosed. University of Melbourne spin-out PredicTx is dismantling this legacy approach, utilizing advanced AI to analyze existing patient CT scans, deliver precision medicine to the bedside, and return a massive 100x financial rerate to hospital networks.
Asset over thematic: Centuria’s Andrew Essey warns against ‘blanket strategies’ as global capital eyes Australia
Relying solely on broad macroeconomic trends is the single biggest mistake property investors make today. Centuria Capital CIO Andrew Essey explains why asset-level “lettability” always trumps the overarching sector thematic, and reveals where global institutional capital is quietly pivoting to capture high-octane returns.
Material gains: Swinburne spin-out EntroMat takes aim at $160b global market
Traditional metallurgy has hit a performance wall. Discover how Swinburne University spin-out EntroMat is leveraging physics-based AI and circular critical minerals to engineer high-entropy alloys capable of surviving the world’s most extreme industrial environments.
Backed By Leading Investment Groups and Family Offices
